OPDIVO (Bristol-Myers Squibb Australia Pty Ltd)
Product name
OPDIVO
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days)
Active ingredients
nivolumab
Registration type
EOI
Indication
Non-Small Cell Lung Cancer (NSCLC)
OPDIVO, in combination with platinum-doublet chemotherapy, is indicated for the neoadjuvant treatment of patients with resectable non-small cell lung cancer (NSCLC).